IPH.PA
Innate Pharma SA
Price:  
1.47 
EUR
Volume:  
226,247.00
France | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

IPH.PA EV/EBITDA

-340.5%
Upside

As of 2025-07-15, the EV/EBITDA ratio of Innate Pharma SA (IPH.PA) is -3.18. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IPH.PA's latest enterprise value is 149.04 mil EUR. IPH.PA's TTM EBITDA according to its financial statements is -46.80 mil EUR. Dividing these 2 quantities gives us the above IPH.PA EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 1.7x - 5.8x 2.1x
Forward P/E multiples 8.7x - 11.7x 11.3x
Fair Price (4.56) - (3.08) (3.54)
Upside -409.3% - -308.8% -340.5%
1.47 EUR
Stock Price
(3.54) EUR
Fair Price

IPH.PA EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2025-07-11 -3.24
2025-07-10 -3.26
2025-07-09 -3.30
2025-07-08 -3.26
2025-07-07 -3.30
2025-07-04 -3.29
2025-07-03 -3.28
2025-07-02 -3.28
2025-07-01 -3.30
2025-06-30 -3.28
2025-06-27 -3.35
2025-06-26 -3.33
2025-06-25 -3.26
2025-06-24 -3.24
2025-06-23 -3.30
2025-06-20 -3.41
2025-06-19 -3.53
2025-06-18 -3.56
2025-06-17 -3.52
2025-06-16 -3.55
2025-06-13 -3.61
2025-06-12 -3.66
2025-06-11 -3.73
2025-06-10 -3.80
2025-06-09 -4.00
2025-06-06 -4.06
2025-06-05 -4.06
2025-06-04 -4.08
2025-06-03 -4.11
2025-06-02 -4.09
2025-05-30 -4.17
2025-05-29 -4.19
2025-05-28 -4.14
2025-05-27 -4.06
2025-05-26 -4.15
2025-05-23 -4.15
2025-05-22 -4.16
2025-05-21 -4.13
2025-05-20 -4.14
2025-05-19 -4.10
2025-05-16 -4.06
2025-05-15 -4.06
2025-05-14 -4.13
2025-05-13 -4.20
2025-05-12 -4.24
2025-05-09 -4.31
2025-05-08 -4.37
2025-05-07 -4.26
2025-05-06 -4.07
2025-05-05 -4.04